Navigation Links
MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System
Date:1/31/2008

SAN DIEGO, Jan. 31 /PRNewswire/ -- MedWaves, Inc. announces the receipt of USFDA 510k clearance to market its patented Microwave Coagulation/Ablation System for general surgery use for the coagulation and ablation of soft tissues. The system is comprised of a microwave generator and single patient use sterile devices. The clearance sets the stage for rapid expansion of a product portfolio and indications for use through additional USFDA submissions and clearances. The Company's proprietary technology allows for the development of minimally invasive devices in wide range of sizes, shapes and flexibility to meet clinicians' requirements in bone, liver, lung and other tumors.

About The Avecure(TM) Ablation System

MedWaves Microwave Coagulation/Ablation System overcomes limitations of existing microwave and radiofrequency (RF) thermal ablation technologies, the standard of treatment for oncology patients who are not candidates for surgery. Initially the Company focused on the general use of its coagulative technology with a high percentage of the anticipated use in patients with bone, liver and lung tumors. For these patients, adjunctive use of microwave ablation can assist in the curative and/or palliative goals of standard therapies e.g. chemotherapy and/or radiation. It can be an option for patients where other thermal modalities are not possible due to tumor size or location. The system offers potential advantages over RF thermal ablation methods in the following ways:

-- Consistency and predictability of lesion creation

-- Ability to treat large lesions (over 3 cm)

-- Increased safety due to the elimination of grounding pads and the

resultant skin burns due to poor contact

-- More even distribution of the thermal energy delivery in the tissues

that is not dependent upon low impedance paths that can be

unpredictable

-- Microwave energy delivery is not affected by high impedance (less

conductive) tissues providing another option for thermal therapy

-- Range of probe designs for maximum flexibility to match tumor

geometries

Unique to other microwave coagulation/ablation systems the MedWaves Microwave Coagulation/Ablation System provides potential advantages in the following ways:

-- Provides clinicians with an automatic temperature regulated

coagulation/ablation process that allows the clinician to control

precisely the tissue temperature generated throughout the

coagulation/ablation process

-- The Company's proprietary probe design provides thermal monitoring that

is highly correlated with tissue temperature with minimal temperature

offset

-- The Company's proprietary probe designs can coagulate/ablate the same

volume of tissue using 50% to 70% less power than other microwave

systems

About MedWaves, Inc.

MedWaves, Inc. develops novel and proprietary microwave ablation technology for the minimally invasive coagulation/ablation of soft tissues and tumors. The Company's management team has extensive experience in the medical device marketplace. MedWaves' clinical advisory board membership includes renowned surgeons from UCSD, City of Hope and The Cushier Skills Center. MedWaves, Inc. is located in San Diego, California, USA.

Contact information: Ted Ormsby, President/CEO

16760 W Bernardo Drive

San Diego, CA 92127

858-946-0015 ext: 238

Email: tedormsby@avecure.com

Website: http://www.medwaves.com


'/>"/>
SOURCE MedWaves, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MQ Associates, Inc. Announces Completion of Tender Offer and Consent Solicitation Relating to its 12 1/4% Senior Discount Notes due 2012
2. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
3. Webcast Alert: HCA Announces 4Q-Year End 07 Earnings Report
4. Pennsylvania Governor Rendell Announces $1.8 Million Investment to Add Nurses, Improve Nurse Education Grants Awarded to Recipients in 28 Counties
5. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
6. Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
7. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
8. Skinvisible Announces Licensing Agreement for Adapalene
9. Aflac Incorporated Announces Fourth Quarter Results
10. Hologic Announces Two-For-One Stock Split
11. Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Pittsburgh, PA (PRWEB) , ... May 26, 2016 ... ... transplantation, and one that has a significant negative impact on long-term patient survival, ... to date. The results, published online this week in the Journal of Thoracic ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James ... Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the ... founder of Retina Group of New York , is a Board Certified ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of Life ... announced the organization has earned its ISO 13485 certification, indicating the company’s quality ... all rules and policies associated with ISO quality standard 13485. , BSI ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... offering campers a multitude of activities from daily practices, arts & crafts, discussions, ... Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ yoga, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
Breaking Medicine Technology: